You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric Antigen Receptors

Showing 1 - 25 of 5,490
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia in Remission Trial in Suzhou (CD19 CAR-T cells and CD19 positive feeder T cells)

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • CD19 CAR-T cells and CD19 positive feeder T cells
  • Suzhou, Jiangsu, China
  • +2 more
May 18, 2022

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

Brain Tumor, Recurrent, Brain Tumor, Refractory Trial in Houston (HER2-specific T cells)

Recruiting
  • Brain Tumor, Recurrent
  • Brain Tumor, Refractory
  • HER2-specific T cells
  • Houston, Texas
  • +1 more
May 3, 2022

Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)

Not yet recruiting
  • Head and Neck Cancer
  • +3 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023

Glioblastoma Multiforme Trial in Chapel Hill (CAR.B7-H3T cells infusion)

Recruiting
  • Glioblastoma Multiforme
  • CAR.B7-H3T cells infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 25, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Germany (Cyclophosphamide (Non-IMP,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • Cyclophosphamide (Non-IMP, Lymphodepletion)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +4 more
Jul 24, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • CD19-CAR(Mem) T-cells
  • +5 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 5, 2022

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • CD19.CAR-CD28Z T Cells - dose escalation 2
  • CD19.CAR-CD28Z T Cells - dose escalation 1
  • Houston, Texas
  • +1 more
Feb 10, 2022

Leukemia, B-Cell Trial in Houston (Autologous TriCAR T-cells and lymphodepletion chemo)

Not yet recruiting
  • Leukemia, B-Cell
  • Autologous TriCAR T-cells and lymphodepletion chemotherapy
  • Houston, Texas
  • +1 more
Nov 3, 2021

Prostate Cancer Trial in Germany (Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), UniCAR02-T-pPSMA)

Recruiting
  • Prostate Cancer
  • Cyclophosphamide (Non-IMP)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +3 more
Jan 24, 2022

Acute Myeloid Leukemia (AML) Trial in Germany (Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP))

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Cyclophosphamide (Non-IMP)
  • +3 more
  • Ulm, Baden-Württemberg, Germany
  • +5 more
Dec 28, 2021

Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor Trial in Houston ((C7R)-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Diffuse Intrinsic Pontine Glioma
  • +3 more
  • (C7R)-GD2.CART cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Feb 7, 2022

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

Not yet recruiting
  • Lymphoma
  • Chimeric Antigen Receptor
  • (no location specified)
Oct 24, 2023

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Relapsed Neuroblastoma
  • +6 more
  • C7R-GD2.CART cells
  • +2 more
  • Houston, Texas
  • +1 more
Nov 12, 2021

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)

Not yet recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • LB2102
  • (no location specified)
Jan 10, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023